Understanding how lymphocyte activation is controlled in the immune system
Mechanisms of Control of Lymphocyte Activation and Proliferation by a Critical Signaling Integrator
This study is looking at how certain immune cells, called B and T cells, get activated and grow, focusing on a protein called CARD11 that helps send important signals for their function, with the goal of finding new ways to treat lymphomas by understanding how changes in CARD11 can lead to uncontrolled cell growth.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-10730542 on NIH RePORTER |
What this research studies
This research investigates the mechanisms by which lymphocytes, specifically B and T cells, are activated and proliferate in response to immune signals. It focuses on a critical protein called CARD11, which plays a key role in transmitting signals that activate NF-κB, a pathway essential for lymphocyte function. By studying how mutations in CARD11 can lead to uncontrolled cell growth in certain types of lymphomas, the research aims to uncover potential therapeutic targets for treating these cancers. Patients may benefit from insights gained into how to better control lymphocyte behavior in diseases like lymphoma.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Diffuse Large B Cell Lymphoma (DLBCL) or other related lymphomas characterized by abnormal lymphocyte activation.
Not a fit: Patients with lymphomas that do not involve CARD11 mutations or those with other unrelated conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments for lymphomas by targeting the mechanisms that cause uncontrolled lymphocyte proliferation.
How similar studies have performed: Previous research has shown promising results in targeting signaling pathways involved in lymphocyte activation, indicating that this approach may lead to significant advancements in lymphoma treatment.
Where this research is happening
Baltimore, United States
- Johns Hopkins University — Baltimore, United States (Active)
Researchers
- Principal investigator: Pomerantz, Joel L — Johns Hopkins University
- Study coordinator: Pomerantz, Joel L
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.